← All trials
NCT01208662
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- Sep 1, 2018
- Completion date
- Sep 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 660
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Emory UniversityCollaborator
- University of MichiganCollaborator
- Duke UniversityCollaborator
- University of California, San FranciscoCollaborator
- University of ChicagoCollaborator
- Stanford UniversityCollaborator
- University of ArizonaCollaborator
- Eastern Maine Medical CenterCollaborator
- University of California, San DiegoCollaborator
- University of PittsburghCollaborator
- Ochsner Health SystemCollaborator
- Newton-Wellesley HospitalCollaborator
- University of FloridaCollaborator
- Northwell HealthCollaborator
- Ohio State UniversityCollaborator
- Columbia UniversityCollaborator
- Wayne State UniversityCollaborator
- University of South FloridaCollaborator
- University of Texas at HoustonCollaborator
- Cornell UniversityCollaborator
- Cape Cod HealthcareCollaborator
- Millennium PharmaceuticalsCollaborator
- Wake Forest UniversityCollaborator
- Baylor UniversityCollaborator
- CelgeneCollaborator
- State University of New York, BrooklynCollaborator
- Vanderbilt UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
- University of UtahCollaborator
- University of WashingtonCollaborator
- Temple UniversityCollaborator
- Harvard UniversityCollaborator
- Oregon Health and Science UniversityCollaborator
- State University of New York, BuffaloCollaborator
- University of Alabama, BirminghamCollaborator
- University of MississippiCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
- City of Hope National Medical CenterCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.